LIRAGLUTIDE

Liraglutide is a GLP‑1 receptor agonist that enhances insulin secretion, suppresses glucagon, and delays gastric emptying. Used for type 2 diabetes and weight management. Side effects include nausea, vomiting, diarrhea, gallbladder disease, pancreatitis risk, and injection‑site reactions.

Product Description


Mechanism of Action

LIRAGLUTIDE (ID 32070) demonstrates a high‑granularity biochemical interaction profile spanning catalytic‑domain modulation, multi‑layer signalling interference, mitochondrial‑network recalibration, redox‑state restructuring, ion‑flux redistribution, membrane‑electrochemical modulation, cytoskeletal‑architecture remodelling and transcription‑factor axis reprogramming. Its molecular topology supports interactions with catalytic residues, allosteric regulatory surfaces, transmembrane helices, hydrophobic receptor pockets, nucleotide‑binding cavities, redox-buffer modules and polymeric scaffolding proteins—enabling broad influence across metabolic, genomic, electrophysiological and structural regulatory networks.

Mechanistically, LIRAGLUTIDE may reshape phosphorylation‑flow geometry across ERK/MAPK/JNK/p38 cascades, modulate PI3K–AKT survival‑pathway architecture, alter G‑protein coupling logic, redistribute Ca²⁺ microdomains, shift IP₃/DAG signal amplitude, and recalibrate cAMP–PKA oscillatory behaviour. Mitochondrial effects include ETC‑complex rebalancing, ATP/ADP flux modulation, ROS‑threshold displacement, mitochondrial‑membrane potential polarity shifts and ER–mitochondria bidirectional stress‑signal integration.

Advanced Research Applications

  • Kinome‑scale catalytic‑cascade interference and pathway reconstruction
  • Ultra‑resolution receptor/ligand docking and conformational‑transition modelling
  • UPR/ER‑stress, mitophagy, autophagy and oxidative‑stress crosstalk research
  • Deep multi‑omics network reconstruction (RNA‑seq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal tension‑mapping, polymer turnover and mechano‑signalling analytics
  • Apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos modelling
  • Machine‑learning SAR/QSAR pipelines for predictive molecular optimisation

Toxicodynamics & Hazard Spectrum

  • Rapid ROS accumulation and antioxidant‑buffer system collapse
  • Mitochondrial fragmentation, membrane‑potential failure or ETC inhibition
  • Severe Na⁺/K⁺/Ca²⁺ ion‑homeostasis disruption
  • Cytoskeletal depolymerisation, actin/tubulin instability and loss of cellular mechanics
  • Membrane‑integrity failure and lipid‑bilayer thinning
  • NF‑κB, STAT and IRF inflammatory‑axis hyperactivation
  • Engagement of multi‑axis programmed‑cell‑death pathways
  • Epigenetic drift across methylation/acetylation domains

For expert laboratory research only — not intended for biological or therapeutic exposure.

Datasheet


Molecular Formula

C172H265N43O51

Molecular Weight

3751 g/mol

CAS Number

204656-20-2

Storage Condition

Prior to first use, Victoza should be stored in a refrigerator between 36 °F to 46 °F (2 °C to 8 °C). Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze Victoza and do not use Victoza if it has been frozen. After initial use of the Victoza pen, the pen can be stored for 30 days at controlled room temperature (59 °F to 86 °F; 15 °C to 30 °C) or in a refrigerator (36 °F to 46 °F; 2 °C to 8 °C). Keep the pen cap on when not in use. Victoza should be protected from excessive heat and sunlight. Always remove and safely discard the needle after each injection and store the Victoza pen without an injection needle attached. This will reduce the potential for contamination, infection, and leakage while also ensuring dosing accuracy.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Liraglutide; 204656-20-2; NN2211; Saxenda; victoza

IUPAC/Chemical Name

(2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid

InChl Key

YSDQQAXHVYUZIW-QCIJIYAXSA-N

InChl Code

InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/16134956;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download